A5063936702- Pituitary Gland Disorders and Treatments
- Growth Hormone and Insulin-like Growth Factors
- Adrenal and Paraganglionic Tumors
- Adrenal Hormones and Disorders
- Hormonal Regulation and Hypertension
- Neuroendocrine Tumor Research Advances
- Sexual Differentiation and Disorders
- Hormonal and reproductive studies
- Cancer, Hypoxia, and Metabolism
- Ophthalmology and Eye Disorders
- Diet and metabolism studies
- Ovarian function and disorders
- Stress Responses and Cortisol
- Sperm and Testicular Function
- Glioma Diagnosis and Treatment
- Thyroid Disorders and Treatments
- Genetic and Clinical Aspects of Sex Determination and Chromosomal Abnormalities
- Effects and risks of endocrine disrupting chemicals
- Hypothalamic control of reproductive hormones
- Vitamin D Research Studies
- Parkinson's Disease Mechanisms and Treatments
- Myasthenia Gravis and Thymoma
- Neuroblastoma Research and Treatments
- Sexual function and dysfunction studies
- Glycogen Storage Diseases and Myoclonus
University of Naples Federico II
2016-2025
Federico II University Hospital
2014-2024
UNESCO
2023-2024
Children's Hospital of Pittsburgh
2024
Ludwig-Maximilians-Universität München
2024
University College London
2024
The University of Texas Southwestern Medical Center
2024
Oregon Medical Research Center
2023
Erasmus MC
2016
Ospedali Riuniti di Ancona
2016
Patients with Cushing's disease (CD) mainly die because of cardiovascular accidents. The aim this study was to evaluate whether patients CD still have increased risk and suffer from premature atherosclerosis once cured. Fifteen cured for a long term period (5 yr), 30 sex-and age-matched controls, body mass index (BMI)-matched controls were included in study. BMI; waist hip ratio (WHR); systolic (SBP) diastolic (DBP) blood pressures; serum total, low density lipoprotein (LDL), high (HDL)...
The role of dopamine agonists in the treatment Cushing's disease (CD) has been previously debated.The aim this study was to evaluate effectiveness short-term (3 months) and long-term (12-24 with cabergoline patients CD.20 CD unsuccessfully treated by surgery entered study. Cabergoline administered at an initial dose 1 mg/wk, a monthly increase mg, until urinary cortisol levels normalized or maximal 7 mg/wk achieved. responsiveness evaluated according changes excretion. A decrease greater...
Adrenal insufficiency in patients with classic 21-hydroxylase deficiency congenital adrenal hyperplasia (CAH) is treated glucocorticoid replacement therapy. Control of adrenal-derived androgen excess usually requires supraphysiologic dosing, which predisposes to glucocorticoid-related complications. Crinecerfont, an oral corticotropin-releasing factor type 1 receptor antagonist, lowered androstenedione levels phase 2 trials involving CAH.
Cardiovascular accidents represent the most important cause of death in patients with Cushing's syndrome. This prospective study aims at evaluating carotid arteries by echo-Doppler ultrasonography and clinical metabolic markers atherosclerosis 25 disease (CD) before after 1 yr remission. Thirty-two sex- age-matched subjects (control-1) 32 body mass index-matched (control-2) served as controls. At diagnosis, CD had higher index, waist to hip ratio (WHR), total, low-density...
Whether the withdrawal of treatment in patients with nontumoral hyperprolactinemia, microprolactinomas, or macroprolactinomas is safe and effective has been unclear. We performed an observational, prospective study cabergoline (a dopamine-receptor agonist) such patients.The population included 200 patients--25 105 70 macroprolactinomas. Withdrawal was considered if prolactin levels were normal, magnetic resonance imaging (MRI) showed no tumor (or reduction 50 percent more, at a distance more...
The role of dopamine agonist treatment in corticotroph pituitary tumors is controversial. aim this study was to evaluate D2 receptor expression 20 and correlate it the vitro effect agonists on ACTH secretion vivo short-term cabergoline cortisol secretion. evaluated by receptor-ligand binding, immunohistochemistry, RT-PCR. A 50% or more decrease daily urinary levels considered a significant clinical response. At specific binding [125I]epidepride found 80% cases. immunostaining 75% 83.3% cases...
BACKGROUND: Gender differences in tumor size are supposed to exist hyperprolactinemia since microadenomas more commonly found women and macroadenomas men. Whether this reflects only a delay diagnosis men or true gender difference pathogenesis is still unclear. OBJECTIVE: To prospectively analyze the presentation response cabergoline treatment 219 consecutive newly diagnosed patients with hyperprolactinemia. DESIGN: An open prospective design. SUBJECTS: Of of which 145 were women; 107 had...
Chronic exposure to hypercortisolism has significant impact on patient's health and health-related quality of life (HRQoL), as demonstrated with generic questionnaires. We have developed a disease-generated questionnaire evaluate HRQoL in patients Cushing's syndrome (CS; CushingQoL). Objective Validate the CushingQoL CS clinical practice conditions. Design Observational, international, cross-sectional study. Methods A total 125 were recruited by 14 investigators from Spain, France, Germany,...